Cargando…

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

BACKGROUND: Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Giacomo, Cavalli, Giulio, Campochiaro, Corrado, Della-Torre, Emanuel, Angelillo, Piera, Tomelleri, Alessandro, Boffini, Nicola, Tentori, Stefano, Mette, Francesca, Farina, Nicola, Rovere-Querini, Patrizia, Ruggeri, Annalisa, D'Aliberti, Teresa, Scarpellini, Paolo, Landoni, Giovanni, De Cobelli, Francesco, Paolini, John F, Zangrillo, Alberto, Tresoldi, Moreno, Trapnell, Bruce C, Ciceri, Fabio, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430344/ https://www.ncbi.nlm.nih.gov/pubmed/32835256 http://dx.doi.org/10.1016/S2665-9913(20)30170-3

Ejemplares similares

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
por: Cremer, Paul C, et al.
Publicado: (2021)

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis
por: Ciceri, Fabio, et al.
Publicado: (2023)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

Adult-onset Still’s disease complicated by Guillain-Barré syndrome
por: Farina, Nicola, et al.
Publicado: (2023)

Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2021)

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2020)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave
por: Palumbo, Diego, et al.
Publicado: (2021)

High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19
por: Ripa, Marco, et al.
Publicado: (2022)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients
por: Mushtaq, Junaid, et al.
Publicado: (2020)

P1638: CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IS A RISK FACTOR FOR PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH COVID-19.
por: Aletti, Federico Mario, et al.
Publicado: (2023)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
por: Ciceri, Fabio, et al.
Publicado: (2020)

Pulmonary Vascular Thrombosis in COVID-19 Pneumonia
por: De Cobelli, Francesco, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials
por: Belletti, Alessandro, et al.
Publicado: (2021)

505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2021)

Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2022)

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
por: Di Franco, Manuela, et al.
Publicado: (2014)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study
por: Conte, Caterina, et al.
Publicado: (2021)

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
por: Campochiaro, Corrado, et al.
Publicado: (2021)

Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19
por: Ramirez, Giuseppe A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vrfakc55dhvfje311mps7mree